A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications

Recruiting now

Conditions studied: Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

In brief

To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound

Key facts

Study ID

NCT07332117

Run by

Royal Brompton & Harefield NHS Foundation Trust

People needed

30

Starts

2025-09-09

Expected to finish

2026-04-01

Last updated by the study team

2026-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
• Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)
• Subject aged > 18 years
• Able to willingly give consent

You may not qualify if…

• Co-morbidities currently requiring enteral feeding
• Weight loss > 10% in preceding 3-6 months
• Significant musculoskeletal issues that may impact muscle mass
• End of life care (expected < 6 weeks left to live)
• Previous anti-fibrotic use
• Currently on > Prednisolone 10mg daily
• Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)
• Heart failure
• Pregnancy

Where it is running

• Royal Brompton Hospital — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.